SpringerLink
Log in

Sotatercept: First Approval

  • ADISINSIGHT REPORT
  • Published:
Drugs Aims and scope Submit manuscript

Abstract

Sotatercept (sotatercept-csrk; WINREVAIRTM) is an activin signalling inhibitor that is being developed by Merck and Co., Inc. (Rahway, NJ, USA) for the treatment of pulmonary arterial hypertension. Sotatercept recently received approval in the USA for the treatment of adults with pulmonary arterial hypertension [World Health Organisation (WHO) Group 1] to increase exercise capacity, improve WHO functional class and reduce the risk of clinical worsening events. This article summarizes the milestones in the development of sotatercept leading to this first approval for pulmonary arterial hypertension.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (Germany)

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Merck Sharp & Dohme LLC. WINREVAIR™ (sotatercept-csrk) for injection, for subcutaneous use: US prescribing information. 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761363s000lbl.pdf. Accessed 21 May 2024.

  2. Nabeh OA, Saud AI, Amin B, et al. A systematic review of novel therapies of pulmonary arterial hypertension. Am J Cardiovasc Drugs. 2024;24(1):39–54.

    Article  CAS  PubMed  Google Scholar 

  3. Merck Sharp & Dohme. FDA approves Merck's WINREVAIR(Tm) (sotatercept-csrk), a first-in-class treatment for adults with pulmonary arterial hypertension (PAH, WHO* Group 1) [media release]. 26 Mar 2024. http://www.merck.com.

  4. Merck. Our pipeline at a glance. 2024. https://www.merck.com/research/product-pipeline/. Accessed 21 May 2024.

  5. Celgene Corporation. Acceleron Pharma announces global collaboration with Celgene Corporation on ACE-011 program for cancer-related bone loss [media release]. 21 Feb 2008. http://www.celgene.com.

  6. Acceleron Pharma. Acceleron to develop sotatercept in pulmonary arterial hypertension [media release]. 19 Sep 2017. http://www.acceleronpharma.com.

  7. United States Securities and Exchange Commission. Acceleron Pharma Inc. Form 10-K. 2020. https://www.sec.gov/Archives/edgar/data/1280600/000128060021000017/xlrn-20201231.htm#i9b3066fc79274057bca4cb67fd38312b_10. Accessed 21 May 2024.

  8. Merck. Merck completes acquisition of Acceleron Pharma Inc [media release]. 22 Nov 2021. https://www.merck.com.

  9. Bristol-Myers Squibb. Bristol-Myers Squibb completes acquisition of Celgene, creating a leading biopharma company [media release]. 20 Nov 2019. https://news.bms.com.

  10. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension. N Engl J Med. 2021;384(13):1204–15.

    Article  CAS  PubMed  Google Scholar 

  11. Hoeper MM, Badesch DB, Ghofrani HA, et al. Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension. N Engl J Med. 2023;388(16):1478–90.

    Article  CAS  PubMed  Google Scholar 

  12. Humbert M, McLaughlin V, Gibbs JSR, et al. Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension. Eur Respir J. 2023;61(1):2201347.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Waxman AB, Systrom DM, Manimaran S, et al. SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension [abstract]. Circ Heart Fail. 2024. https://doi.org/10.1161/CIRCHEARTFAILURE.123.011227.

    Article  PubMed  Google Scholar 

Download references

Funding

The preparation of this review was not supported by any external funding.

Author information

Authors and Affiliations

  1. Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand

    Connie Kang

Authors
  1. Connie Kang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Connie Kang.

Ethics declarations

Authorship and Conflict of Interest

During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Connie Kang is a salaried employee of Adis International Ltd/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.

Ethics Approval, Consent to Participate, Consent to Publish, Availability of Data and Material, Code Availability

Not applicable.

Additional information

This profile has been extracted and modified from the AdisInsight database. AdisInsight tracks drug development worldwide through the entire development process, from discovery, through pre-clinical and clinical studies to market launch and beyond.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (PDF 180 KB)

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Kang, C. Sotatercept: First Approval. Drugs (2024). https://doi.org/10.1007/s40265-024-02058-9

Download citation

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s40265-024-02058-9

Search

Navigation